All manuscripts
Publications T-Cells G-Rex®100M-CS G-Rex®24 Well Plate G-Rex®500M-CS G-Rex®6 Well Plate G-Rex®6M Well Plate

Scalable GMP-compliant gene correction of CD4+ T cells with IDLV template functionally validated in vitro and in vivo

Published Journal Molecular Therapy - Methods & Clinical Development

Share
No image preview

Overview

Developed a GMP process for gene correction of CD4+ T cells. Medium-scale experiments used G-Rex® 6-6M, and large-scale used G-Rex® 100CS or 500CS for cell expansion.

What this paper found

A good manufacturing practice-compliant, scalable process corrected the CD40LG gene in human CD4+ T cells by Cas9 ribonucleoprotein editing with an integrase-defective lentiviral vector donor template, shortening the protocol from 21 to 13 days. Delivering the vector at day 2 before electroporation, together with LentiBoost, gave optimal editing efficiency, and immunomagnetic enrichment of LNGFR-positive cells on day 6 produced a nearly pure product with 46-fold cumulative growth. Patient cells were edited with similar or better efficiency and kept stem cell memory and central memory phenotypes. Edited cells engrafted in NSG mice with stable editing in blood, bone marrow and spleen. At full scale up to 500 × 10^6 cells were electroporated, yielding up to 20 × 10^9 cells.

Note: The large-scale and full-scale runs were performed with healthy donor cells; the authors note that large-scale runs with patient cells may be warranted in the future.

The process is expected to yield at least 1 × 10^10 cells per patient in a single run, which is in the range of doses used in other T cell therapies. — Claudia Asperti, Daniele Canarutto, Simona Porcellini, Francesca Sanvito, Francesca Cecere, Valentina Vavassori, Samuele Ferrari, Elisabetta Rovelli, Luisa Albano, Aurelien Jacob, Lucia Sergi Sergi, Elisa Montaldo, Francesca Ferrua, Luis Ignacio González-Granado, Vassilios Lougaris, Raffaele Badolato, Andrea Finocchi, Anna Villa, Marina Radrizzani, Luigi Naldini, Molecular Therapy - Methods & Clinical Development

Study details

Authors
Claudia Asperti, Daniele Canarutto, Simona Porcellini, Francesca Sanvito, Francesca Cecere, Valentina Vavassori, Samuele Ferrari, Elisabetta Rovelli, Luisa Albano, Aurelien Jacob, Lucia Sergi Sergi, Elisa Montaldo, Francesca Ferrua, Luis Ignacio González-Granado, Vassilios Lougaris, Raffaele Badolato, Andrea Finocchi, Anna Villa, Marina Radrizzani, Luigi Naldini
Institution
San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Hospital, Milan, Italy · Vita-Salute San Raffaele University, Milan, Italy · Pediatric Immunohematology Unit and BMT Program, IRCCS San Raffaele Hospital, Milan, Italy · Pathology Unit, IRCCS San Raffaele Hospital, Milan, Italy · Primary Immunodeficiencies Unit, Department of Pediatrics, Research Institute Imas12 (i+12), Hospital 12 de Octubre, Madrid, Spain · School of Medicine, Complutense University, Madrid, Spain · Pediatrics Clinic and Institute for Molecular Medicine A. Nocivelli, Department of Clinical and Experimental Sciences, University of Brescia and ASST-Spedali Civili of Brescia, Brescia, Italy · Academic Department of Pediatrics (DPUO), Research Unit of Clinical Immunology and Vaccinology, Bambino Gesu Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy · Istituto di Ricerca Genetica e Biomedica, Consiglio Nazionale Delle Ricerche (IRGB-CNR), Unit of Milan, Italy
Journal
Molecular Therapy - Methods & Clinical Development
Year
2023
PMID / PMC
PMID: 37693944 · PMC
G-Rex® model(s)
G-Rex®100M-CS, G-Rex®24 Well Plate, G-Rex®500M-CS, G-Rex®6 Well Plate, G-Rex®6M Well Plate
Cell type(s)
T-Cells
Application area
Other
Study phase
Preclinical

How G-Rex® was used

CD4+ T cells were activated in G-Rex® 24-6-6M on day 0 for the small- and medium-scale protocol, transduced with IDLV and electroporated with Cas9 RNP on day 2, enriched for LNGFR on day 6 and frozen on day 13. Medium-scale runs starting from 5-10 × 10^6 cells at day 2 used G-Rex® 6-6M cell culture systems (Wilson Wolf). Large- and full-scale runs starting from 100-500 × 10^6 cells at day 2 were activated and cultured in G-Rex® 100CS or G-Rex® 500CS (Wilson Wolf), and expansion in the G-Rex® bioreactor scaled from G-Rex® 6M to G-Rex® 500M-CS, yielding up to 20 × 10^9 cells.

Note: In the large- and full-scale process the cells were handled in a closed system apart from the cell wash and centrifugation steps.

Explore related

Full citation

Asperti C, Canarutto D, Porcellini S, et al. Scalable GMP-compliant gene correction of CD4+ T cells with IDLV template functionally validated in vitro and in vivo. Mol Ther Methods Clin Dev. 2023;30:546-557.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →